CoChat

Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration

Open access

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

BACKGROUND: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). OBJECTIVE: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. METHODS: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer's disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. RESULTS: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. CONCLUSION: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-200608

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Research works printed but not linked: 4

  1. Meeter LH, 2017, Nat Rev Neurol, 19, 109
  2. Abu-Rumeileh S, 2019, Alzheimers Res Ther, 12, 1
  3. Novelli G, 1970, Arch Psicol Neurol Psichiatr, 47, 278
  4. Novelli G, 1986, Arch Psicol Neurol Psichiatr, 47, 477

Cited by

See all 113

Metadata

Authors
Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., Fostinelli, S., Giunta, M., Gasparotti, R., Zetterberg, H., Blennow, K., & Borroni, B.
Affiliations
  • University of Brescia (IT)
  • King's College London (GB)
  • University of Gothenburg (SE)
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
  • Centro San Giovanni di Dio Fatebenefratelli (IT)
  • Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
  • Ljubljana University Medical Centre (SI)
Corresponding author
Borroni, Barbara
Venue
Journal of Alzheimer’s Disease
Published
2020-08-14
Volume
77
Issue
3
Pages
1129-1141
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W3049719602
Cited by
113
References
80
Citations by year
2026: 11 · 2025: 24 · 2024: 22 · 2023: 21 · 2022: 16 · 2021: 17 · 2020: 1
FWCI
9.97
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
Funders
  • Alzheimer's Drug Discovery Foundation (2016862, FO2017-0243, 201809, 2017-00915, #ALFGBG-715986, 201809–2016862, JPND2019-466-236, 201809-2016615, #RDAPB‐201809‐2016615, AF-742881)
  • EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
  • European Commission (JPND2019‐466‐236)
  • Ministero della Salute (2018-)
  • Hjärnfonden (FO2017‑0243, FO2017, ALFGBG-715986, JPND2019-466-236)
  • Vetenskapsrådet (2017-00915, (#ALFGBG-715986, 681712, 2018-, JPND2019-466-236, FO2017-0243, 2018-02532)
  • UK Dementia Research Institute (#2017-00915)
  • H2020 European Research Council (681712)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
glial fibrillary acidic protein, serum biomarkers
MeSH terms
Aged, Aged, 80 and over, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Biomarkers, Frontotemporal Lobar Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. https://app.cochat.ai/papers/10.3233/jad-200608
The paper
Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., Fostinelli, S., Giunta, M., Gasparotti, R., Zetterberg, H., Blennow, K., & Borroni, B. (2020). Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-200608

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.